Reading QTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QTI free→Reading QTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track QTI free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality is not assessable since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, QTI trades below typical levels. Peer multiples imply a price about 56% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.85. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.85 QTI trades at 2× p/s, below its 3× p/s peer median. Our $8.90 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 57% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.43x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.03 → $-0.22 (-633.3% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$184.
How much price usually moves either way.
On a bad day, this stock has moved -$814.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,059.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth speeds up, it may help QT Imaging's performance in a maturing sector.
Confirms:Sector revenue growth shows a rise back toward 10% or higher.
Disproves:Sector revenue growth remains below 10% or continues to slow.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for QTI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement On May 15, 2026, QT Imaging Holdings, Inc. (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Representative ”) as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten offering (the “ Offering ”) of 1,200,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common S…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
QTI QT Imaging Holdings Inc | Below typical Show detailsSector percentile: 16 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to achieve approximately $39 million in revenue for the fiscal year 2026.
Stated in 3 of last 3 quarters. Revenue grew from $846,832 in 2024-Q4 to $8,275,070 in 2025-Q4, indicating strong growth. The company is focused on achieving $39 million in revenue for 2026, with the trajectory showing positive momentum.
“The Company reaffirms guidance for 2026 revenue to be approximately $39 million.”
“Looking ahead, we expect revenue in 2026 to be approximately $39 million.”
“The Company expects 2026 revenue to be approximately $39 million.”
The company is expanding its market reach through new distribution agreements.
Newly stated in 2026-Q1. The company entered into a Distribution Agreement with Al Naghi Medical Co., aiming to expand its market reach. This strategic move is expected to support revenue growth, although specific financial impacts are not yet evident.
“QT Imaging entered into a Distribution Agreement with Al Naghi Medical Co.”
The company has initiated an underwritten offering of 1,200,000 shares to raise capital.
Newly stated in 2026-Q2. The company initiated an underwritten offering of 1,200,000 shares to raise capital. This move is part of its capital allocation strategy, but the financial impact of this offering is not yet reflected in the financials.
“QT Imaging entered into an underwriting agreement for an offering of 1,200,000 shares.”
Why it matters: The earnings report will show if the company is improving its financial situation. Investors will look for signs of recovery.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue decline or flat growth year over year.
Results of Operations and Financial Condition. On May 13, 2026, QT Imaging Holdings, Inc. (the “ Company ”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “ Current Report ”) and is incorporated by reference herein. The information included in Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” with the…
Results of Operations and Financial Condition. On March 25, 2026, QT Imaging Holdings, Inc. (the “ Company ”) issued a press release announcing its financial results for the full fiscal year and the three months ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “ Current Report ”) and is incorporated by reference herein. The information included in Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall…
Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Base Salary Increase and Bonus On March 20, 2026 (the “ Approval Date ”), the Board of Directors (the “ Board ”) of QT Imaging Holdings, Inc. (the “ Company ”), upon the recommendation of the Compensation Committee of the Board (the “ Compensation Committee ”), (i) approved an increase in the base salary for Dr. Raluca Dinu,…
Results of Operations and Financial Condition. On February 18, 2026, QT Imaging Holdings, Inc. (the “ Company ”) issued a press release announcing its financial results for the full fiscal year and the three months ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “ Current Report ”) and is incorporated by reference herein. The information included in Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and sha…